Prema Abraham

4.6k total citations · 1 hit paper
22 papers, 1.8k citations indexed

About

Prema Abraham is a scholar working on Ophthalmology, Radiology, Nuclear Medicine and Imaging and Surgery. According to data from OpenAlex, Prema Abraham has authored 22 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Ophthalmology, 12 papers in Radiology, Nuclear Medicine and Imaging and 2 papers in Surgery. Recurrent topics in Prema Abraham's work include Retinal Diseases and Treatments (19 papers), Retinal Imaging and Analysis (11 papers) and Retinal and Optic Conditions (9 papers). Prema Abraham is often cited by papers focused on Retinal Diseases and Treatments (19 papers), Retinal Imaging and Analysis (11 papers) and Retinal and Optic Conditions (9 papers). Prema Abraham collaborates with scholars based in United States and Germany. Prema Abraham's co-authors include Huibin Yue, Laura Wilson, Naveed Shams, Susan Schneider, David M. Brown, Tsontcho Ianchulev, Carl D. Regillo, Clement K. Chan, Jeffrey S. Heier and Quan Dong Nguyen and has published in prestigious journals such as Ophthalmology, American Journal of Ophthalmology and Investigative Ophthalmology & Visual Science.

In The Last Decade

Prema Abraham

20 papers receiving 1.7k citations

Hit Papers

Randomized, Double-Masked, Sham-Controlled Trial of Ranib... 2008 2026 2014 2020 2008 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1
    2008 693 citations Carl D. Regillo, David M. Brown et al. American Journal of Ophthalmology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Prema Abraham United States 12 1.8k 1.5k 210 58 29 22 1.8k
Majid Anderesi United Kingdom 5 1.8k 1.0× 1.5k 1.0× 358 1.7× 89 1.5× 60 2.1× 5 1.9k
Ryan Rich United States 7 855 0.5× 576 0.4× 173 0.8× 29 0.5× 22 0.8× 9 968
Myrte B. Breukink Netherlands 17 977 0.6× 575 0.4× 143 0.7× 79 1.4× 21 0.7× 28 1.1k
Yehia Hashad United States 11 1.6k 0.9× 1.1k 0.8× 138 0.7× 11 0.2× 15 0.5× 17 1.7k
Phillip Lai United States 6 916 0.5× 695 0.5× 132 0.6× 23 0.4× 28 1.0× 14 969
James Warburton Switzerland 5 885 0.5× 663 0.5× 158 0.8× 20 0.3× 47 1.6× 8 950
Lebriz Altay Germany 15 701 0.4× 431 0.3× 180 0.9× 29 0.5× 121 4.2× 33 804
Johannes P. H. van de Ven Netherlands 15 498 0.3× 323 0.2× 197 0.9× 21 0.4× 70 2.4× 18 565
Wendy Yee Murahashi United States 4 2.5k 1.4× 1.5k 1.1× 249 1.2× 62 1.1× 52 1.8× 6 2.5k
Tommaso Bacci Italy 13 498 0.3× 281 0.2× 122 0.6× 15 0.3× 35 1.2× 33 623

Countries citing papers authored by Prema Abraham

Since Specialization
Citations

This map shows the geographic impact of Prema Abraham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Prema Abraham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Prema Abraham more than expected).

Fields of papers citing papers by Prema Abraham

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Prema Abraham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Prema Abraham. The network helps show where Prema Abraham may publish in the future.

Co-authorship network of co-authors of Prema Abraham

This figure shows the co-authorship network connecting the top 25 collaborators of Prema Abraham. A scholar is included among the top collaborators of Prema Abraham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Prema Abraham. Prema Abraham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chan, Clement K., Maziar Lalezary, Prema Abraham, et al.. (2022). Prophylactic Ranibizumab to Prevent Neovascular Age-Related Macular Degeneration in Vulnerable Fellow Eyes. Ophthalmology Retina. 6(6). 484–494. 12 indexed citations
2.
Chan, Clement K., David Sarraf, Prema Abraham, et al.. (2020). Meticulous multimodal analysis of aflibercept therapy for submacular vascularized pigment epithelial detachment associated with neovascular AMD in a prospective case series, the EVEN study. American Journal of Ophthalmology Case Reports. 20. 100916–100916. 5 indexed citations
3.
Lalezary, Maziar, Steven Lin, Clement K. Chan, et al.. (2017). Prophylactic Ranibizumab for Exudative age-related macular degeneration (AMD) in Vulnerable Eyes with Non-Exudative AMD Trial (PREVENT): A prospective controlled clinical trial. Investigative Ophthalmology & Visual Science. 58(8). 410–410. 2 indexed citations
4.
Chen, Xuejing, Mayss Al‐Sheikh, Clement K. Chan, et al.. (2016). TYPE 1 VERSUS TYPE 3 NEOVASCULARIZATION IN PIGMENT EPITHELIAL DETACHMENTS ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. Retina. 36(Supplement 1). S50–S64. 31 indexed citations
5.
6.
Sarraf, David, Clement K. Chan, Ehsan Rahimy, & Prema Abraham. (2013). PROSPECTIVE EVALUATION OF THE INCIDENCE AND RISK FACTORS FOR THE DEVELOPMENT OF RPE TEARS AFTER HIGH- AND LOW-DOSE RANIBIZUMAB THERAPY. Retina. 33(8). 1551–1557. 59 indexed citations
7.
Chan, Clement K., Prema Abraham, & David Sarraf. (2012). High-dose ranibizumab therapy for vascularized pigment epithelial detachment. Eye. 26(6). 882–885. 10 indexed citations
8.
Chan, Clement K., Prema Abraham, & David Sarraf. (2012). Response to Talks et al. Eye. 26(12). 1600–1601. 1 indexed citations
9.
Brown, David M., Jeffrey S. Heier, Thomas A. Ciulla, et al.. (2011). Primary Endpoint Results of a Phase II Study of Vascular Endothelial Growth Factor Trap-Eye in Wet Age-related Macular Degeneration. Ophthalmology. 118(6). 1089–1097. 82 indexed citations
10.
Abraham, Prema, Huibin Yue, & Laura Wilson. (2010). Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-Related Macular Degeneration: PIER Study Year 2. American Journal of Ophthalmology. 150(3). 315–324.e1. 334 indexed citations
11.
Heier, Jeffrey S., David Brown, Thomas A. Ciulla, et al.. (2010). Ranibizumab for Choroidal Neovascularization Secondary to Causes Other Than Age-Related Macular Degeneration: A Phase I Clinical Trial. Ophthalmology. 118(1). 111–118. 38 indexed citations
12.
Heier, Jeffrey S., Syed Mahmood Shah, Afsheen Khwaja, et al.. (2010). Two-Year Results of the READ 2 Study: Ranibizumab for Edema of the Macula in Diabetes. 51(13). 5842–5842. 2 indexed citations
13.
14.
Nguyen, Quan Dong, Syed Mahmood Shah, Jeffrey S. Heier, et al.. (2009). Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study. Ophthalmology. 116(11). 2175–2181.e1. 264 indexed citations
15.
16.
Callanan, David, et al.. (2008). Clinical Evaluation of the Safety and Efficacy of TRIESENCETM (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL for Visualization of Vitreous and Membranes in Pars Plana Vitrectomy. Investigative Ophthalmology & Visual Science. 49(13). 5601–5601. 1 indexed citations
17.
Regillo, Carl D., David M. Brown, Prema Abraham, et al.. (2008). Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1. American Journal of Ophthalmology. 145(2). 239–248.e5. 693 indexed citations breakdown →
18.
Chan, Clement K., Carsten H. Meyer, Jeffrey G. Gross, et al.. (2007). RETINAL PIGMENT EPITHELIAL TEARS AFTER INTRAVITREAL BEVACIZUMAB INJECTION FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina. 27(5). 541–551. 136 indexed citations
19.
Hsu, Jason, Richard Kaiser, Arunan Sivalingam, et al.. (2007). INTRAVITREAL BEVACIZUMAB (AVASTIN) IN CENTRAL RETINAL VEIN OCCLUSION. Retina. 27(8). 1013–1019. 1 indexed citations
20.
Abraham, Prema, et al.. (1984). Liver scan in hepatic amebiasis: correlation with clinical and biochemical studies.. PubMed. 50(5). 408–16.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Majid Anderesi Breakdown of academic impact, for papers by Ryan Rich Breakdown of academic impact, for papers by Myrte B. Breukink Breakdown of academic impact, for papers by Yehia Hashad Breakdown of academic impact, for papers by Phillip Lai Breakdown of academic impact, for papers by James Warburton Breakdown of academic impact, for papers by Lebriz Altay Breakdown of academic impact, for papers by Johannes P. H. van de Ven Breakdown of academic impact, for papers by Wendy Yee Murahashi Breakdown of academic impact, for papers by Tommaso Bacci
Rankless by CCL
2026